A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Velpatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 08 Mar 2018 Results assessing pharmacokinetics and safety of Velpatasvir and Sofosbuvir/Velpatasvir in subjects with hepatic impairment in two studies (phase I study of Velpatasvir and a pharmacokinetic sub-study of a phase III study of SOF/VEL-ASTRAL-4), published in Clinical Pharmacokinetics Journal.
- 28 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Aug 2013 Planned end date changed from 1 Oct 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.